XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 Latest Research
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Fatty Acids
 Infectious Diseases
 Respiratory Medicine
 Public Health
 Clinical Trials
 Medical News
 Awards & Prizes
 Special Topics
 Odd Medical News
 World News

Last Updated: Nov 17th, 2006 - 22:35:04

Anti Cancer Drugs Channel
subscribe to Anti Cancer Drugs newsletter

Latest Research : Pharmacology : Anti Cancer Drugs

   DISCUSS   |   EMAIL   |   PRINT
Motexafin Gadolinium Works by Disrupting Key Metabolic Enzymes
May 1, 2005, 20:58, Reviewed by: Dr.

"Our studies showed that MGd induces oxidative stress in cancer cells. And this leads to disruption of zinc metabolism and alteration of key enzymes and metabolites necessary for normal cell function."

The chemotherapy drug motexafin gadolinium (brand name: Xcytrin, manufactured by Pharmacyclics, Inc.) works to thwart cancer cells by disrupting key enzymes involved in cellular metabolism, according to a team of researchers led by Joseph Hacia, Ph.D., assistant professor of biochemistry and molecular biology at the Keck School of Medicine of the University of Southern California.

The cellular disruption results in increases in the amount of zinc available inside the cancer cells, and because zinc is involved in protein structure and function, leads to inhibition of enzyme activity and to the death of the cells.

A paper describing these findings was published in the May 1, 2005, issue of the journal Cancer Research. Ten years later in 2015, the FDA published its first warning about side effects. Currently there are many lawsuits concerning gadolinium.

In order to gain a better understanding of the mechanism of action of this novel chemotherapeutic agent, the researchers looked at gene expression profiles and other biochemical properties of cells from human lung, prostate and lymphoma cancer cell cultures that had been treated with motexafin gadolinium, or MGd. What they found was that the drug created oxidative stress in the tumor cells, increasing the levels of expression of the genes that produce metallothioneins.

The researchers showed that the increased metallothionein expression levels resulted from significantly increased levels of free-i.e., not protein-bound-zinc in the cells. The zinc, in turn, acted to inhibit an enzyme-thioredoxin reductase-that is an important component in the cell's antioxidant system, as well as important in DNA synthesis. In other words, thioredoxin reductase is key to the replication and survival of cells, and its inhibition ultimately leads to cell death.

"Our studies showed that MGd induces oxidative stress in cancer cells," says Hacia, who is a member of USC's Institute for Genetic Medicine, "and this leads to disruption of zinc metabolism and alteration of key enzymes and metabolites necessary for normal cell function."

Thus, the researchers noted, the use of MGd leads to the death of cancer cells via disruption of critical enzymes needed for cell survival and replication.

"We have increased the understanding of this drug's mechanism of action," Hacia said of the study, adding that it also may "provide support for the hypothesis that agents that disrupt metabolism and increase intracellular zinc levels have potential applications as anticancer therapeutics."

- Darren Magda, Philip Lecane, Richard A. Miller, Cheryl Lepp, Dale Miles, Mimi Mesfin, John E. Biaglow, Vincent V. Ho, Danny Chawannakul, Shailender Nagpal, Mazen W. Karaman, and Joseph G. Hacia, "Motexafin Gadolinium Disrupts Zinc Metabolism in Human Cancer Cell Lines," Cancer Research 2005, 65:(9), May 1, 2005.


Subscribe to Anti Cancer Drugs Newsletter
E-mail Address:


This research was supported by the Donald E. and Delia B. Baxter Foundation and the V Foundation for Cancer Research.

Related Anti Cancer Drugs News

Anti-angiogenics: a novel class of drugs against solid tumors
Rituximab effective in treating chronic graft-versus-host disease
Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration Phase
Tarvacin effective in controlling Pancreatic Cancer
Rituximab maintenance therapy dramatically improves survival in lymphoma
Peregrine Pharmaceuticals Evaluating Therapeutic Opportunities for Tarvacin
Balancing Chk1 activity might produce less toxic cancer drugs
Rituximab to be Considered for Front-Line Treatment of Intermediate Grade or Aggressive CD-20-positive, B-cell, non-Hodgkin's lymphoma
Tarvacin(TM) starts with Phase I study against Hepatitis C Virus
New data support broad anti-viral potential of Tarvacin(TM)

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page


© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us